(Q24243043)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

1 reference

title

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

author name string

M Clerico

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

F Faggiano

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

J Palace

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

G Rice

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

L Durelli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

publication date

16 April 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

6 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

page(s)

CD005278

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

6 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Acute demyelinating optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Axonal damage in acute multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Imaging axonal damage of normal-appearing white matter in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Therapy with glatiramer acetate for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

Meta-Analysis of Clinical Trials with Copolymer 1 in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005278.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD005278.PUB3

2 references

Consolidated OpenCitations Corpus – April 2017

3177084

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18425915%20AND%20SRC:MED&resulttype=core&format=json

6 January 2020

3177084

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

3177084